Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Aura Biosciences raises $30m for nanoparticle cancer treatment

December 21, 2017 By Sarah Faulkner

Aura BiosciencesAura Biosciences has closed a $30 million Series C round with funding from new investors like Arix Bioscience and Lundbeckfonden Ventures, as well as existing investors, including the estate of former-Genzyme CEO Henri Termeer, who died earlier this year.

The privately-held biotech is developing a light-activated nanoparticle therapy for patients with ocular melanoma. Aura said it plans to use its newly-acquired funds to expand infrastructure for its Phase Ib/II clinical trial.

The company also expects to expand its footprint in Cambridge, Mass., next year.

“This year has been one of incredible momentum for Aura, with interim positive data reported from our Phase Ib/II study of AU-011 and enthusiasm from key opinion leaders in ocular oncology across the country,” founder & CEO Elisabet de los Pinos said in prepared remarks.

“We are pleased to enter 2018 with the renewed support of existing investors and to welcome Lundbeckfonden Ventures and Arix Bioscience to our Series C syndicate. We look forward this year to laying the groundwork for Phase III clinical development, furthering our commitment to enabling earlier treatment intervention for patients with ocular melanoma.”

“The Aura team has proven nimble while retaining a strong scientific rigor as it has made the transition to a clinical-stage company,” Casper Breum, senior partner at Lundbeckfonden Ventures, added.

“We believe that this timely investment will propel the company’s preparations for late-stage studies of AU-011, with the potential to provide a safe and effective therapy where plaque radiation or enucleation are the only options currently,” Mark Chin, investment director at Arix Bioscience, said.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Nanoparticles, Oncology, Optical/Ophthalmic, Pharmaceuticals, Research & Development Tagged With: Aura Biosciences

IN CASE YOU MISSED IT

  • FDA approves Tandem Diabetes’ advanced hybrid closed-loop controller
  • Senate confirms Dr. Stephen Hahn to lead FDA
  • 3M to sell drug-delivery biz to Altaris Capital Partners for $650m
  • Medicina recalls IV Luer Slip syringes
  • Eitan Group signs service agreement with Integrated Medical Systems
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS